Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | SMPD3 | Q9NY59 | 2/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.30 |
| ▸ | PDE5A | O76074 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6860396 | 0.78 | PIK3CG (0.41) | KDM4EALDH1A1HPGDSMPD3AXL | |
| SCHEMBL19520117 | 0.75 | NUDT1 (0.46) | ALDH1A1 | |
| SCHEMBL24983903 | 0.72 | PIK3CG (0.35) | KDM4EALDH1A1HPGDPIK3CG | |
| SCHEMBL5496407 | 0.69 | NUDT1 (0.56) | KDM4EALDH1A1HPGDSMPD3AXL | |
| SCHEMBL26354530 | 0.69 | PIK3CG (0.33) | PIK3CGPDE5A | |
| SCHEMBL20348407 | 0.69 | ALDH1A1 (0.38) | KDM4EALDH1A1HPGDSMPD3SMN1; SMN2 | |
| SCHEMBL21937448 | 0.69 | PIK3CG (0.45) | SMPD3AXLPIK3CG | |
| SCHEMBL11155397 | 0.69 | DRD4 (0.40) | KDM4EALDH1A1HPGDSMN1; SMN2GABRA5 | |
| SCHEMBL13377380 | 0.68 | KDM4E (0.33) | KDM4EALDH1A1HPGDSMPD3AXL | |
| SCHEMBL23176172 | 0.68 | BRD4 (0.33) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200039998-A1 | AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND METHODS OF USE THEREOF | Epizyme, Inc. | 2020-02-06 | — | — | US | disclosed |
| US-9920061-B2 | Imidazo[1,5-A]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders | LYSOSOMAL THERAPEUTICS INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-20170349599-A1 | IMIDAZO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039998-A1 | AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND METHODS OF USE THEREOF | HNMT, BHMT, EHMT2 | KDM4E 222/4885ALDH1A1 180/4885HPGD 204/4885 |
| US-20170349599-A1 | IMIDAZO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GAA, GBA2 | KDM4E 659/4885ALDH1A1 1121/4885HPGD 2135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.